Dodge plans gas-powered Charger but will cut cheaper electric variant
Dodge is pulling the plug, so to speak, on its base model electric Charger Daytona, the R/T, as it deals with slow sales, but don't expect what appears to be a limited-edition run of vehicles to turn into collector's items, according to a key industry watcher.
'Rarity does not make a collectible. You need to have demand for it,' said Sam Fiorani, vice president of global vehicle forecasting for AutoForecast Solutions. 'You can't presume that this will be a Charger Daytona of 1970. They couldn't sell those originally and years later they were collectible.'
Fiorani said it's risky to bet on a car of today becoming something that brings big dollars in the years to come, even when the numbers of those made and sold are relatively small.
Still, Dodge will continue to offer the more powerful and expensive electric Charger Daytona Scat Pack for the upcoming model year, even as it prepares to launch several gas-powered versions.
While it's not clear how many Dodge Charger Daytonas will be produced this year, so far the sales picture is showing a fairly light impact. Electric Charger sales — the company did not distinguish between versions — for the first three months of this year were at 1,947. Granted, they were just beginning to arrive in showrooms in January after months of delays.
However, the automaker likely had higher hopes. Fiorani noted that he'd recently driven by a Dodge dealership and saw a row of Chargers waiting to be sold.
In a statement, Dodge CEO Matt McAlear said 'production of the Dodge Charger Daytona R/T is postponed for the 2026 model year as we continue to assess the effects of U.S. tariff policies. The Charger's flexible, multi-energy STLA Large platform allows us to focus on the Charger Daytona Scat Pack's performance as the world's quickest and most powerful muscle car, add the new four-door model to the Charger mix for the 2026 model year and lean into the new Charger SIXPACK models that will launch in the second half of the year.'
Sixpack refers to the engine, the inline-six Hurricane, which will come in 550-horsepower or 420-horsepower variants.
The current electric Scat Pack promises a peak power base of 630 horsepower with a limited push-button burst to 670 horsepower called the Power Shot. The Dodge website lists the Scat Pack all-wheel drive with a starting price of $73,985, excluding destination charge.
Adding gas-powered versions to the lineup is not a surprise, as Dodge had previously said that was the plan. However, the decision, reported earlier by MoparInsiders.com, to end the electric R/T's run so soon does highlight how the market has changed, both in terms of the slower adoption of electric vehicles and President Donald Trump's embrace of tariffs. The Charger Daytona is assembled at the Windsor Assembly Plant in Ontario, but the batteries initially were to come from South Korea.
Fiorani offered some perspective on the potential tariff impact, however.
'Everybody is leaning on tariffs for every change in production or sales, whether real or not,' he said.
Market realities are, however, what they are.
More: Detroit automakers want Silicon Valley talent, but need Michigan engineering knowledge
'The idea that an internal combustion engine version would hit the market better at the moment is a strong one,' according to Fiorani. 'Buyers haven't warmed up to EVs as a performance vehicle yet, especially since every EV is a performance model now.'
Fiorani noted also that the company's planned shift in production volume toward the gas-powered Charger would also take the focus off the less expensive EV version — the R/T was listed with a starting price of $59,595, not counting destination.
'(They) kind of want to focus on the vehicle that will make money versus the entry-level models that will sell on price,' Fiorani said.
The moves for Dodge follow news that Ram is also adjusting its electric plans. Crain's Detroit Business, citing a memo to suppliers, reported this week that the electric Ram 1500 REV would be delayed until summer 2027, a year later than what the automaker told the Free Press in January, and the extended range Ramcharger is being pushed from later this year to early next year.
More: U.S. auto industry wants trade deal with Canada and Mexico to be Trump's priority
The company, in a statement provided by spokesman Nick Cappa, cited "slowing consumer demand for half-ton" battery electric pickups and noted that "we also are extending the quality validation period for the Range Extended Ram to support a successful launch and the highest build quality."
Contact Eric D. Lawrence: elawrence@freepress.com. Become a subscriber. Submit a letter to the editor at freep.com/letters.
This article originally appeared on Detroit Free Press: Dodge pivots on future EV offerings after lackluster sales
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting
DAZALS did not meet its primary endpoint of improved outcome in the ALS Functional Rating Scale-Revised (ALSFRS-R) in patients who received dazucorilant compared to patients who received placebo DAZALS met its secondary endpoint of improved overall survival at week 24 of the study in patients who received 300 mg of dazucorilant compared to patients who received placebo Exploratory analysis at the one-year mark shows continued significant improvement in overall survival between patients who received 300 mg of dazucorilant and those who received placebo only Corcept seeking guidance from United States and European regulators on optimum path forward REDWOOD CITY, Calif., June 05, 2025--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, presented results from its DAZALS study of dazucorilant in patients with ALS at the European Network to Cure ALS (ENCALS) 2025 annual meeting. The presentation can be found here. DAZALS is a randomized, double-blind, placebo-controlled Phase 2 study in which 249 patients with ALS were randomized to receive either 150 mg of dazucorilant, 300 mg of dazucorilant or placebo, daily for 24 weeks. Patients who completed the treatment period were eligible to enroll in a long-term extension study in which all patients received 300 mg of dazucorilant. The primary endpoint in DAZALS was the difference in ALSFRS-R between patients who received dazucorilant and those who received placebo. Overall survival was a secondary endpoint. Although DAZALS did not meet its primary endpoint, patient survival significantly improved. At week 24 of the study, no deaths had occurred in the 83 patients who received 300 mg of dazucorilant, while there were five deaths in the 82-patient placebo group (p-value of 0.02). An exploratory analysis conducted at the one-year mark shows the survival benefit has continued. Patients randomized to 300 mg of dazucorilant lived significantly longer than patients who received placebo and did not switch to 300 mg of dazucorilant in the extension study. The difference between groups was pronounced, with a hazard ratio of 0.16 (p-value: 0.0009). See Figure 1. A similar survival benefit was observed in patients who received 300 mg of dazucorilant for greater than 24 weeks, either in the treatment period or in the extension study, compared to patients who received either placebo or 150 mg of dazucorilant for 24 weeks and did not receive dazucorilant in the extension study (hazard ratio: 0.36; p-value 0.02). See Figure 2. The extension study is ongoing. Dazucorilant has demonstrated an acceptable safety profile, with 92 percent of adverse events being mild to moderate in severity. The frequency of severe and serious adverse events in patients who received dazucorilant was similar to those who received placebo. Mild to moderate, dose-related, transient abdominal pain was the most common adverse effect. "The improvement in overall survival, first noted in the DAZALS study at six months, continues to be seen at one-year. This finding deserves our full attention in service to patients with this tragic disease. Progress in the development of new ALS treatments is of critical importance," said Leonard H. van den Berg, M.D., Ph.D., Professor and Chair in the Department of Neurology, UMC Utrecht Brain Centre, Utrecht, The Netherlands, and Principal Investigator in the DAZALS study. "Medications that can extend life for patients with ALS are urgently needed. We are working with regulatory authorities to determine the optimal path for advancing dazucorilant," said Bill Guyer, PharmD, Corcept's Chief Development Officer. "We would like to thank the patients, their families and care partners, as well as the investigators, doctors and clinic staff involved in this study." About the DAZALS Study DAZALS is a randomized, double-blind, placebo-controlled Phases 2 trial in which 249 patients with ALS were randomized 1:1:1 to receive either 150 mg of dazucorilant, 300 mg of dazucorilant or placebo daily for 24 weeks. Patients who completed the treatment period were eligible to enroll in the long-term extension study in which all patients received 300 mg of dazucorilant. Baseline patient characteristics, including the ENCALS risk score, time from diagnosis, ALSFRS-R total score, and bulbar onset, were consistent across study arms. The DAZALS primary endpoint was the difference in change from baseline during the study's 24-week treatment period in ALSFRS-R score between patients who received dazucorilant and those who received placebo. Key secondary endpoints include overall survival and quality of life. DAZALS was conducted at sites in Europe, the United States and Canada. About Amyotrophic Lateral Sclerosis (ALS) ALS, also known as Lou Gehrig's disease or motor neuron disease, is a fatal degenerative neurologic disorder that affects more than 55,000 people in the United States and Europe. ALS causes muscles to weaken and, as the disease progresses, severely impairs patients' ability to speak, eat, move and breathe. There is increasing evidence that patients with ALS, particularly those with rapid disease progression, exhibit elevated or abnormal cortisol levels. A patient's life expectancy after diagnosis is two to five years. About Dazucorilant Dazucorilant is a selective cortisol modulator that binds to the glucocorticoid receptor but does not bind to the body's other hormone receptors. Corcept is studying it as a potential treatment for ALS and other neurologic disorders. Dazucorilant is proprietary to Corcept and is protected by composition of matter, method of use and other patents. The U.S. Food and Drug Administration has granted dazucorilant Fast Track Designation and orphan drug status for the treatment of ALS in the United States. About Corcept Therapeutics For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California. For more information, visit Forward-Looking Statements Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations, which are subject to risks and uncertainties that might cause our actual results to differ materially from those such statements express or imply. These risks and uncertainties are set forth in our SEC filings, which are available at our website and the SEC's website. In this press release, forward-looking statements include those concerning the development of dazucorilant as a treatment for patients with ALS, including the pace, conduct, timing and outcome of DAZALS and its associated long-term extension study, as well as oversight or requirements that may be imposed by the FDA or other regulatory authorities. We disclaim any intention or duty to update forward-looking statements made in this press release. View source version on Contacts Investor inquiries:ir@ Media inquiries:communications@
Yahoo
2 hours ago
- Yahoo
Ohio Senate GOP moves to give wealthiest Ohioans tax cut
Senate President Rob McColley, R-Napoleon, speaks at the Ohio Senate Republican Budget Press Conference. Sen. Jerry Cirino, R-Kirtland, the chair of the Senate Finance Committee, stands in the background. Photo: Morgan Trau, WEWS Ohio Republican senators have proposed a flat income tax for the state's top earners, which would result in a projected $1 billion loss in the general revenue fund. Bailey Williams is like the average Ohioan — earning less than six figures a year. According to census data, the median income in the state is about $68,000. He's worried about the Senate's newly proposed state budget. 'The services that made me who I am today, public education made me who I am today. I worry about those opportunities being there for my younger siblings,' Williams said. He is also a researcher with the nonpartisan organization Policy Matters Ohio and is evaluating a budget provision — one that creates a flat income tax of 2.75%. There are three income tax brackets in Ohio. Those making up to $26,000 do not need to pay state income tax. Ohioans earning between $26,000 and $100,000 pay a tax of 2.75%. Those making more than $100,000 have to pay 3.5%. Senate President Rob McColley (R-Napoleon) said that the highest earners in the state will have their income tax payment reduced to 2.75%. 'Every tax cut we do in the future will involve every single person equally, on a percentage basis,' McColley said. State data reveals that this could result in a loss of about $1.1 billion in the General Revenue Fund. How would Ohio make up the deficit from the tax? 'One of two ways,' Williams said. 'We're going to see increases in regressive taxes, most likely the sales tax, or we have to make do with less — less government services.' Many cuts for programs that benefit lower-income families have already been proposed in the budget. Funding for schools, Medicaid, libraries, lead abatement, food banks and child care face funding decreases from the current status or from the governor's budget. When McColley was asked how he defends cuts to Medicaid, lead poisoning prevention and child care while allowing a lower tax rate for wealthier Ohioans, he said the 'growth in Medicaid spending has been exponential.' According to the Legislative Service Commission, a nonpartisan agency that works with the legislature, the proposed budget would result in a 4% decrease in spending, with billions of dollars in cuts. He said that there was already an 'awful lot' of lead program funding and said that they were keeping child care the same as before. However, the budget would cut the governor's proposal of offering Publicly Funded Child Care to families earning up to 160% of the federal poverty level, keeping it at the current 145% threshold. 'No multimillionaire needs a $10,000 tax cut bankrolled by cutting lead abatement or Medicaid,' Williams said. McColley said the elimination of 11% of the state's income tax revenue would not actually impact funding because he predicts companies will move to Ohio to take advantage of that lower tax rate. 'A lower tax burden has had a positive economic development and brought more jobs to the state,' McColley said. 'It's brought more investment in the state.' The budget will continue to be heard, and a final version will need to be agreed upon by the Senate and House by the end of June. Click here to learn more about the House's passed budget. Follow WEWS statehouse reporter Morgan Trau on Twitter and Facebook. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX SUPPORT: YOU MAKE OUR WORK POSSIBLE
Yahoo
3 hours ago
- Yahoo
Dial in the Savings With T-Mobile's 5-Year Price Guarantee
The following content is brought to you by PCMag partners. If you buy a product featured here, we may earn an affiliate commission or other compensation. If you're looking for ways to tighten your purse strings these days—and who isn't—T-Mobile has got just the thing. The carrier's new and plans basically replace and build on T-Mobile's previous . At first glance, they include many of the same popular perks as the older plans, such as unlimited talk, text, and premium data, free Netflix Standard with ads and Apple TV+, and on most domestic flights on Alaska, American, Delta, and United. So, what's new about these two plans? For starters, both offer even more high-speed hotpot data and a five-year price guarantee* to help you mind your budget. Existing and new customers can also save some pretty substantial money on the , compared to older T-Mobile plans and similar offerings from competitive mobile carriers. Here's how the new Experience plans break down and stack up. T-Mobile's plan (starting at $90 per month) is similar to the Go5G Plus plan in that it offers free Netflix Standard with ads, free Apple TV+, and 5G device upgrades every two years. What's new is that Experience More bumps up the high-speed hotspot data to 60 GB, with unlimited 600kbps after that. Experience More also offers unlimited text in Mexico and Canada, plus 15GB of high-speed data while you're there, which is handy for travelers. You'll also nab 5GB of high-speed data to use in over 215 countries across the world. If you burn through your hotspot data, (starting at $105 per month) is T-Mobile's most data-heavy plan. It includes all the perks of the Experience More plan, but you'll get a shiny new 5G smartphone every year instead of every two years; plus 250GB of high-speed hotspot data, which is over four times the amount of the Experience More plan. You'll also score 30GB of high-speed data in Canada and Mexico and 15GB of international high-speed data, a perk if you're planning a far-flung summer vacay. Experience Beyond sweetens the deal even more by throwing in free Hulu with ads, in addition to the plan's free Netflix Standard with ads and free Apple TV+. Starting July 2025, the Beyond plan will also include free service, which is pretty cool. The new service will allow you to use your phone in places where you get zero bars. If you don't need unlimited high-speed data, T-Mobile's (starting at $55 per month) is also sticking around. This pared-down yet value-packed plan includes unlimited talk and text, 50GB of high-speed data, and an unlimited 3G hotspot. Note that the streaming add-ons cost extra. Device upgrades and T-Mobile's five-year price lock also aren't available with this plan. For a plan with one line, T-Mobile claims the Experience More and Experience Beyond packages will cost per month than similar unlimited data plans from competitors. For families with three lines, that savings potentially bumps up to T-Mobile's five-year price guarantee also outperforms other big carriers, as most competitors offer only a three-year price guarantee, or no price lock at all. The new Experience plans are a no-brainer if you're looking to and spend less dough. You'll get unlimited talk, text, and data on the nation's , more high-speed hotspot data, free entertainment apps, international data for your summer trips, and a guaranteed five-year price lock. You can also potentially save up to at least 20% when compared to the competitor's plans. If you can save this big on your mobile bill over the next five years, that's not chump change. *Guarantees monthly price of on-network talk, text, & 5G data for accounts activating on an Experience plan. Savings with 3rd line free via mo. bill credits vs. comparable available plans plus optional streaming; plan features and taxes & fees may vary. Credits stop if you cancel any lines. Qualifying new account & credit req'd. See exclusions & details at
